Opportunities and Challenges of RNA Interference Therapeutics in Oncology.
10.3779/j.issn.1009-3419.2022.102.20
- Author:
Rui CHEN
1
;
Yan XU
2
Author Information
1. Clinical Pharmacology Research Center,
Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
2. Department of Respiratory and Critical Care Medicine,
Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Delivery systems;
Oncology;
RNA interference
- MeSH:
Humans;
Lung Neoplasms/genetics*;
RNA Interference;
RNA, Small Interfering/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2022;25(7):482-486
- CountryChina
- Language:Chinese
-
Abstract:
As the discovery of RNA interference (RNAi) and the gradual conquering of a series of technical issues, a few of RNAi therapeutics have been approved in the non-tumor field abroad. With the advantages of high specificity, long duration of efficacy, and high success rate of development, RNAi therapeutics have become the emerging field globally. There are no RNAi therapeutics approved in oncology so far, and people are hoping a breakthrough in the field. In the present article, the characteristics and potential anti-tumor mechanism of RNAi therapeutics, difficulties in delivery system and progress in oncology are described, and the potential reasons why their success in non-tumor field is difficult to be simply replicated in tumor field are analyzed, providing reference for research and clinical transformation of RNAi therapeutics in oncology.
.
